Emergent BioSolutions announced April 15 that it has begun the formal process of separating some of its assets to form a separate entity, which will be known as Aptevo Therapeutics Inc. Aptevo will specifically focus on immuno-oncology technology, while Emergent will consolidate its focus on public health.
{iframe}http://bioprepwatch.com/stories/510718356-emergent-files-paperwork-for-new-immuno-oncology-spin-off{/iframe}